We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+44.75%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$175M
AUM Growth
+$89.5M
Cap. Flow
+$53.8M
Cap. Flow %
30.68%
Top 10 Hldgs %
49.35%
Holding
76
New
27
Increased
18
Reduced
14
Closed
15

Top Buys

Rank Stock Value
1
ZYME icon
Zymeworks
ZYME
+$13.2M
2
PRTA icon
Prothena Corp
PRTA
+$7.5M
3
AZN icon
AstraZeneca
AZN
+$7.03M
4
QDEL icon
QuidelOrtho
QDEL
+$4.84M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$4.69M

Top Sells

Rank Stock Value
1
GRFS
Grifois
GRFS
+$7.79M
2
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$6.86M
3
ZYXI
Zynex
ZYXI
+$3.17M
4
AGN
Allergan plc
AGN
+$2.59M
5
UNH icon
UnitedHealth
UNH
+$1.97M

Sector Composition

Rank Sector Weight
1 Healthcare 89.33%
2 Real Estate 0.86%
3 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
26
Humana
HUM
$45B
$2.56M 1.46%
+6,600
New +$2.47M
NVRO
27
DELISTED
NEVRO CORP.
NVRO
$2.25M 1.28%
+18,800
New +$2.23M
IONS icon
28
Ionis Pharmaceuticals
IONS
$9.06B
$2.15M 1.22%
+36,400
New +$2.02M
FOLD
29
DELISTED
Amicus Therapeutics
FOLD
$1.92M 1.09%
127,300
+55,300
+77% +$674K
SRDX
30
DELISTED
Surmodics
SRDX
$1.9M 1.08%
+43,978
New +$1.66M
AXNX
31
DELISTED
Axonics, Inc. Common Stock
AXNX
$1.71M 0.98%
48,800
-14,200
-23% -$489K
HZNP
32
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.65M 0.94%
+29,600
New +$1.27M
RFL icon
33
Rafael Holdings
RFL
$104M
$1.5M 0.86%
106,203
+15,824
+18% +$218K
CRSP icon
34
CRISPR Therapeutics
CRSP
$4.88B
$1.26M 0.72%
17,200
+800
+5% +$46.8K
STAA icon
35
STAAR Surgical
STAA
$1.21B
$1.26M 0.72%
20,428
+12,630
+162% +$516K
SILK
36
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$1.16M 0.66%
+27,711
New +$1.06M
FATE icon
37
Fate Therapeutics
FATE
$291M
$1.13M 0.65%
+33,000
New +$984K
KDMN
38
DELISTED
Kadmon Holdings, Inc.
KDMN
$1.03M 0.59%
200,841
-56,300
-22% -$252K
BHVN
39
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.02M 0.58%
+14,000
New +$745K
CNST
40
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$1M 0.57%
33,400
+15,500
+87% +$558K
VAPO
41
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$889K 0.51%
+2,713
New +$572K
DVAX
42
DELISTED
Dynavax Technologies
DVAX
$887K 0.51%
+100,000
New +$505K
PRVB
43
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$845K 0.48%
+59,900
New +$756K
PODD icon
44
Insulet
PODD
$11.8B
$777K 0.44%
+4,000
New +$765K
MASI
45
DELISTED
Masimo
MASI
$775K 0.44%
+3,400
New +$746K
AXGN icon
46
Axogen
AXGN
$2.46B
$742K 0.42%
80,350
+5,300
+7% +$47.5K
RVNC
47
DELISTED
Revance Therapeutics, Inc.
RVNC
$695K 0.4%
28,469
+16,600
+140% +$328K
LYRA
48
DELISTED
LYRA THERAPEUTICS INC
LYRA
$687K 0.39%
+1,213
New +$887K
PCRX icon
49
Pacira BioSciences
PCRX
$1.06B
$640K 0.36%
12,200
+5,200
+74% +$217K
ATRS
50
DELISTED
Antares Pharma, Inc.
ATRS
$629K 0.36%
229,046
-635,054
-73% -$1.77M
1
2
3

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Soleus Capital Management held 76 positions worth $175M, up 104% from $85.9M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Soleus Capital Management deployed $53.8M of net new capital in Q2 2020, opening 27 new positions and adding to 18 existing holdings. Its largest new stake was Prothena Corp: 674,603 shares worth $7.06M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 98% a quarter earlier, followed by Real Estate and Communication Services.

On the sell side, the largest reduction was Harpoon Therapeutics, Inc. Common Stock, an estimated $6.86M trimmed.

  • Soleus Capital Management's largest Q2 2020 buy was Prothena Corp: 674,603 shares worth $7.06M.
  • Soleus Capital Management added most to Zymeworks in Q2 2020, an estimated $13.2M increase.
  • Soleus Capital Management's biggest Q2 2020 reduction was Harpoon Therapeutics, Inc. Common Stock, cutting an estimated $6.86M.
  • Soleus Capital Management fully exited Grifois in Q2 2020, selling an estimated $7.79M.
  • Soleus Capital Management's ten largest holdings make up 49% of its $175M portfolio in Q2 2020.
  • Soleus Capital Management opened 27 new positions and closed 15 in Q2 2020.
  • Soleus Capital Management's portfolio value rose 104% quarter-over-quarter to $175M.

Based on Soleus Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.